Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Современные возможности лечения колоректального рака
Современные возможности лечения колоректального рака
Ю.А.Барсуков, В.И.Кныш. Современные возможности лечения колоректального рака. Онкология. 2006; 2: 7-16.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Vogel I, Soeth E, Ruder C et al. Disseminated tumor cells in the blood and/or bone marrow of patients with colorectal carcinoma are an independent prognostic factor. Ann. Oncol., 2000; 11 (suppl. 4): 43, abstr. 183.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995 Apr 15;345(8955):939–44.
3. Haller D, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of int-0089. Proc Am Soc Clin Oncol 1998; 17: 256a (Abstr 982).
4. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553–9.
5. Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol, 2003 Aug 1;21(15):2896–903.
6. Grothey A et al. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin, 2002 May 15;97(5):270–7.
7. S. Hensley Alford et al. Stage III colon cancer in the elderly: Adjuvant therapy and survival. Proc Am Soc Clin Oncol 2003 abstr 3008.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–106.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.
10. Cassidy J. et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings ASCO 2004 abstract 3509.
11. Twelves C. et al. Capecitabine as adjuvant treatment for satge III colon cancer. N Engl J Med 2005; 352:269–704.
12. Joseph NE et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr;10(3):213–8.
13. Scheithauer W. et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology 14: 1735–1743, 2003.
2. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet, 1995 Apr 15;345(8955):939–44.
3. Haller D, Catalano PJ, Macdonald JS, Mayer RJ. Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of int-0089. Proc Am Soc Clin Oncol 1998; 17: 256a (Abstr 982).
4. Wolmark N, Rockette H, Mamounas E et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol. 1999; 17: 3553–9.
5. Andre T et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol, 2003 Aug 1;21(15):2896–903.
6. Grothey A et al. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin, 2002 May 15;97(5):270–7.
7. S. Hensley Alford et al. Stage III colon cancer in the elderly: Adjuvant therapy and survival. Proc Am Soc Clin Oncol 2003 abstr 3008.
8. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097–106.
9. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282–92.
10. Cassidy J. et al. Capecitabine (X) vs bolus 5-FU/leucovorin (LV) as adjuvant therapy for colon cancer (the X-ACT study): efficacy results of a phase III trial. Proceedings ASCO 2004 abstract 3509.
11. Twelves C. et al. Capecitabine as adjuvant treatment for satge III colon cancer. N Engl J Med 2005; 352:269–704.
12. Joseph NE et al. Accuracy of determining nodal negativity in colorectal cancer on the basis of the number of nodes retrieved on resection. Ann Surg Oncol. 2003 Apr;10(3):213–8.
13. Scheithauer W. et al. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial Annals of Oncology 14: 1735–1743, 2003.
Авторы
Ю.А.Барсуков, В.И.Кныш
НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
НИИ КО ГУ РОНЦ РАМН им. Н.Н.Блохина, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.